Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postmarketing Study of Repaglinide Plus Long-acting Insulin in Type 2 Diabetes Mellitus
jRCT1080223173Phase 4Completed
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of repaglinide in type 2 diabetes mellitus (T2DM), sponsored by Sumitomo Pharma. Started Apr 2016; status: completed.
02
Drugs
repaglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080223173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223173.